Journal Article

Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC

Yang, Huizhen, Liang, Shuang, Yuan, Shijun, Fu, Shunli, Yang, Han, Zhang, Na, Mu, Weiwei, Sang, Xiao, Zhang, Zipeng, Chang, Lili, Gao, Tong, Liu, Xiaoqing, Liu, Yongjun

2024

Overview

Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown encouraging clinical benefits for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Nevertheless, therapeutic efficacy and wide clinical applicability remain a challenge due to “cold” tumors’ immunological characteristics. Tumor immunosuppressive microenvironment (TIME) continuously natural force for immune escape by extracellular matrix (ECM) infiltration, tumor angiogenesis, and tumor cell proliferation. Herein, we proposed a novel concept by multi-overcoming immune escape to maximize the ICIs combined with antiangiogenic therapy efficacy against HCC. A self-delivery photothermal-boosted-NanoBike (BPSP) composed of black phosphorus (BP) tandem-augmented anti-PD-L1 mAb plus sorafenib (SF) is meticulously constructed as a triple combination therapy strategy. The simplicity of BPSP's composition, with no additional ingredients added, makes it easy to prepare and presents promising marketing opportunities. (1) NIR-II-activated BPSP performs photothermal therapy (PTT) and remodels ECM by depleting collagen I, promoting deep penetration of therapeutics and immune cells. (2) PTT promotes SF release and SF exerts anti-vascular effects and down-regulates PD-L1 via RAS/RAF/ERK pathway inhibition, enhancing the efficacy of anti-PD-L1 mAb in overcoming immune evasion. (3) Anti-PD-L1 mAb block PD1/PD-L1 recognition and PTT-induced ICD initiates effector T cells and increases response rates of PD-L1 mAb. Highly-encapsulated BPSP converted 'cold' tumors into 'hot' ones, improved CTL/Treg ratio, and cured orthotopic HCC tumors in mice. Thus, multi-overcoming immune escape offers new possibilities for advancing immunotherapies, and photothermal/chemical/immune synergistic therapy shows promise in the clinical development of HCC. Graphical Abstract

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Angiogenesis / Angiogenesis inhibitors / Anti-vascular therapy / Antiangiogenics / Biotechnology / Black phosphorus / Cell growth / Cell proliferation / Chemistry / Chemistry and Materials Science / Chemotherapy, Combination / Collagen / Collagen (type I) / Cytotoxicity / Dosage and administration / Drug delivery systems / Drug therapy / Drugs / Effectiveness / Effector cells / Extracellular matrix / Health aspects / Hepatocellular carcinoma / Hepatoma / Immune checkpoint inhibitors / Immune escape / Immune evasion / Immune system / Immunology / Immunotherapy / Inhibitor drugs / Liver cancer / Lymphocytes / Lymphocytes T / Metastases / Microenvironments / Molecular Medicine / Monoclonal antibodies / Nanomedicine / Nanotechnology / PD-1 protein / PD-L1 protein / Pharmaceutical research / Phototherapy / Raf protein / T cells / Technology application / Therapy / Tumor immunosuppressive / Tumors / Vehicles / Women in Nanobiotechnology